Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
Background: Alpelisib was approved for treatment of breast cancer. We assessed the safety signals associated with alpelisib by data mining the FDA pharmacovigilance database. Methods: Data from the second quarter of 2019 to the fourth quarter of 2022 had been retrieved from the FAERS database. Dispr...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2024-03-01
|
| Серія: | Heliyon |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S2405844024036302 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|